Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO1990006123) UTILISATION THERAPEUTIQUE D'AGENTS BLOQUANT L'ENTREE DE CALCIUM DANS LE DYSFONCTIONNEMENT DU NERF RETINIE OU OPTIQUE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

-18-

CLAIMS

1. A method of treating a subject suffering from ischemia or edema of the retina or optic nerve which comprises administering to said subject a therapeutically effective amount of a calcium entry blocker.

2. The method of claim 1, wherein said compound is azaheterocyclic.

3. The method of claim 2, wherein said compound is selected from the group consisting of calcium channel antagonists and excitatory amino acid antagonists.

4. The method of claim 1, wherein said compound is administered topically, parenterally or orally.

5. The method of claim 3, wherein said compound is a calcium channel antagonist.

6. The method of claim 5, wherein said calcium channel antagonist is a dihydropyridine.

7. The method of claim 6, wherein said dihydropyridine is selected from the group consisting of nifedipine, nimodipine, nisoldipine, nitrendipine and 1, l-dimethyl-2-[N-(3,3-diphenylpropyl)-N-methyl-amino] ethyl methyl l,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate hydrochloride.

8. The method of claim 7, wherein said compound is nifedipine.

9. The method of claim 7 , wherein said compound is 1, l-dimethyl-2- [N-(3 ,3-diphenylpropyl)-N-methyl-amino] ethyl methyl l,4-dihydro-2, 6-dimethyl-4-(3-nitropheryl )-3,5-pyridinedicarboxylate hydrochloride.

-19-

10. The method of claim 5, wherein said calcium channel antagonist is a diphenylpiperazine.

11. The method of claim 10, wherein said diphenylpiperazine is selected from the group consisting of cinnarizine and flunarizine.

12. The method of claim 5, wherein said calcium channel antagonist is a phenylalkylamine.

13. The method of claim 12, wherein said phenylalkylamine is selected from the group consisting of verapamil and adipamil.

14. The method of claim 5, wherein said calcium channel antagonist is a benzothiazepine.

15. The method of claim 14, wherein said benzothiazepine is diltiazem.

16. The method of claim 3, wherein said compound is an excitatory amino acid antagonist.

17. The method of claim 16, wherein said excitatory amino acid antagonist is selected from the group consisting of MK-801, 2-APV and CNQX.

18. A method of preventing ischemia or edema of the retina or optic nerve which comprises administering to a subject a prophylactically effective amount of a calcium entry blocker.
19. The method of claim 18, wherein said calcium entry blocker is a compound selected from the group consisting of calcium channel antagonists and excitatory amino acid antagonists .

20. The method of claim 18, wherein said compound is administered topically, parenterally or orally.

21. A method for evaluating a physiologically active compound for the treatment of retinal dysfunction resulting from cellular calcium overload, said method comprising:
administering to a rat suffering from retinal ischemia, a calcium channel modulating amount of a drug, which is a calcium channel antagonist or excitatory amino acid antagonist, wherein said retinal ischemia is a result of occlusion of at least one of the short posterior ciliary arteries and the central retinal artery; and
evaluating at least one of an ERG, histopathology of the retina of said rat or ophthalmoscopic examination of the retina of said rat, as an indication of the effect of said drug.

22. The method according to claim 21, wherein said rat is an adult Sprague-Dawley (albino) rat, Long-Evans pigmented rat, hypertensive Dahl salt-sensitive (albino) rat or spontaneously hypertensive (SHR) (albino) rat.

23. The method according to claim 22, wherein said drug is an azaheterocycle calcium channel antagonist.

24. The method according to claim 22, wherein said drug is an excitatory amino acid antagonist.

25. The method according to claim 21, wherein the a-, and b-waves are determined in said ERG.

26. The method according to claim 21, wherein said occlusion is for 5 to 120 minutes.

27. The method according to claim 22, wherein both the posterior ciliary arteries and/or the central retinal artery are occluded.